权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

HBI-002 to Prevent Anthracycline-Related Cardiotoxicity

HBI-002 可预防蒽环类药物相关的心脏毒性

基本信息

批准号：
10459735
负责人：
Edward Gomperts
金额：
$ 1.69万
依托单位：
HILLHURST BIOPHARMACEUTICALS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-15 至 2023-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10459735
关键词：
Animal Model Animals Anthracycline Attenuated Award Biogenesis Biological Availability Breast Breast Cancer Model Breast Cancer Patient Cancer Model Cancer Patient Canis familiaris Carbon Monoxide Cardiac Cardiac Myocytes Cardiology Cardiotoxicity Cell Death Characteristics Clinical Clinical Research Data Data Set Development Dexrazoxane Dose Doxorubicin Drug Kinetics Effectiveness Exposure to Formulation Gases Gastrointestinal tract structure Goals Hematologic Neoplasms Hemoglobin Hemoglobin concentration result Human Inhalation Inhalation Exposure Injury Investigational Drugs Iron Chelation Kinetics Life Literature Lung Lung Adenocarcinoma Malignant Neoplasms Malignant neoplasm of lung Mitochondria Modality Modeling Morbidity - disease rate Mus Myocardium Oral Oral Administration Ovarian Oxidative Stress Patient Care Patients Pharmaceutical Preparations Pharmacologic Substance Phase Phase I Clinical Trials Phase II Clinical Trials Preparation Prevention Rattus Reporting Research Research Personnel Research Support Risk Safety Seasons Sickle Cell Anemia Small Business Innovation Research Grant Solid Neoplasm Testing Therapeutic Therapeutic Index Toxic effect Toxicology Tumor Burden Wild Type Mouse advanced breast cancer base cancer therapy cardioprotection cardiovascular health clinical development clinically relevant effective therapy experience healthy volunteer improved improved outcome in vivo mouse model novel novel therapeutics potential biomarker pre-clinical preclinical study prevent therapeutic development triple-negative invasive breast carcinoma

项目摘要

PROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patients who receive doxorubicin develop significant cardiac morbidity, and this effect has been shown to be dose dependent. In multiple preclinical studies, we and others have defined the therapeutic potential of low-dose exogenous carbon monoxide (CO) in anthracycline cardiotoxicity prevention, including protecting the cardiomyocyte from cell death and maintaining overall cardiovascular health. To date, inhaled CO gas (iCO) and CO bound to carrier molecules (CORMs) have been the modalities of choice in the majority of animal and in all the clinical studies carried out to study the potential benefit of CO. However, iCO and CORMS are not expected to be pharmaceutically acceptable and viable therapeutic options due to, with iCO, the risk of inadvertent exposure from the presence of compressed CO cylinders as well as difficulties in controlling dosing and, with CORMs, carrier molecule toxicology, stability, and CO release characteristics that have proven to be a substantial barrier to development. The objective of the proposed project is to investigate HBI-002, a novel oral CO drug product that was developed to enable the use of CO to prevent cardiotoxicity from anthracycline use. The safety and tolerability of CO has been demonstrated in eighteen successful Phase 1 and 2 clinical studies in other indications supported by well-defined preclinical data sets that led to approval by the FDA for human testing. HBI-002 comprises an oral formulation containing precise amounts of CO that are not bound to a carrier molecule (i.e. not a CORM) and efficiently absorbed from the gastrointestinal tract. Preclinical in vivo pharmacokinetic studies demonstrated proof-of-concept feasibility, tolerability, and bioavailability. The next step in development is to demonstrate that HBI-002 is effective in clinically relevant animal models of cardiotoxicity from anthracycline use as has been shown with other forms of CO and to better understand the potential mechanism(s) of action. Based upon the substantial literature of CO in preventing anthracycline cardiotoxicity, our central hypothesis that will be tested in this project is: HBI-002 will attenuate Doxorubicin- induced cardiotoxicity through stimulation of mitochondrial biogenesis.

项目总结